Detailed narrative
FDA Regulatory Progress for GraftAssureDx
Insight Molecular Diagnostics is in the latter stages of the FDA review process for GraftAssureDx, targeting marketing authorization later this year. The company received an additional information letter in July, a normal part of the Class II process, and plans an SIR meeting with the FDA to ensure alignment before submitting the final data package. Since March, the amount of samples collected in the study has tripled, and management is pleased with the FDA's engagement timeliness.
Improving Market Landscape and Reimbursement
The market for transplant rejection tests is improving, with Medicare's recently expanded reimbursement guidelines (MolDX LCD) boosting surveillance from 8 to 14 tests in the first 3 years post-kidney transplant. This increased testing frequency strengthens the economic case for bringing dd-cfDNA testing in-house. The company also believes it holds a competitive advantage, being about two years ahead in kitted product development compared to competitors.
Strong Clinical Data and Customer Engagement
GraftAssureDx has demonstrated strong head-to-head data, showing clinical equivalence to leading tests performed at central laboratories. This data, along with leadership in showing how dd-cfDNA can manage antibody-mediated rejection, is driving increased interest from top transplant centers and reference labs. Over half of the top 10 transplant centers in the US are currently working with Insight Molecular Diagnostics through its FDA program or registry.
Financial Management and Commercial Readiness
Core spending decreased from its Q4 2025 peak, leading to a narrowed adjusted EBITDA loss of $7.8 million in Q2 FY26. While cash burn was $10 million in Q2, expected to be the high watermark, the company anticipates approximately $8 million per quarter in H2 FY26. Management believes they are fully staffed to support material revenue growth and are enforcing cost discipline, tying future investments to expected revenue generation.
Total Addressable Market (TAM) Expansion
The previously stated $2 billion total addressable market for kitted transplanted organ testing (kidney) is growing. Increased surveillance testing frequency, therapy monitoring, and expanded organ indications (such as heart transplants, for which a KOL call is planned on August 17) are expected to significantly grow the TAM. The GraftAssure platform is designed to be organ agnostic, supporting future expansion.
International Regulatory and Market Access
The company is progressing with its IVDR submission for Europe and the UK, targeting completion in H2 FY26. Management views the IVDR process as more flexible and easier than FDA requirements. While Switzerland has started paying for some testing and tenders are emerging in other European countries, market access and reimbursement across Europe are largely gated by the approval of anti-CD38 drugs for routine use.
Bio-Rad Partnership and Commercial Strategy
Bio-Rad has been a supportive partner throughout the FDA engagement process. Insight Molecular Diagnostics has an opportunity to negotiate an expanded agreement with Bio-Rad both before and within 90 days after FDA authorization. The partnership is seen as attractive for platform manufacturers due to the potential for high-value molecular content adoption in various lab settings and the ability to build additional content.